This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
iRadimed (IRMD) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how iRadimed (IRMD) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
by Zacks Equity Research
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why "Trend" Investors Would Love Betting on iRadimed (IRMD)
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
3 Reasons Growth Investors Will Love iRadimed (IRMD)
by Zacks Equity Research
iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Momentum in iRadimed (IRMD) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
3 Reasons Why Growth Investors Shouldn't Overlook iRadimed (IRMD)
by Zacks Equity Research
iRadimed (IRMD) could produce exceptional returns because of its solid growth attributes.
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
iRadimed (IRMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 35.29% and 4.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRadimed (IRMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iRadimed (IRMD) Stock Jumps 11.3%: Will It Continue to Soar?
by Zacks Equity Research
iRadimed (IRMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's What Could Help iRadimed (IRMD) Maintain Its Recent Price Strength
by Zacks Equity Research
iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 44.44% and 10.34%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 120.00% and 3.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate iRadimed (IRMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 225.00% and 22.96%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: iRadimed (IRMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRadimed (IRMD) Q1 Earnings Surpass Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.48%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: iRadimed (IRMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRadimed (IRMD) Tops Q4 Earnings Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 53.33% and 1.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.